The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Rachid Lahlil, Fabien Calvo and Abdel-Majid Khatib
Affiliation: Laboratoire de Pharmacologie Experimentale et Clinique, INSERM U 716/ Equipe AVENIR, Institut de Genetique Moleculaire, 27 rue Juliette Dodu, 75010 Paris, France.
The setup of tumorigenesis processes is generally associated with various events leading to abnormal expression of oncogenes and/or tumor suppressor genes. Recently, the expression and/or activity of a range of molecules involved in these processes were reported to require proteolytic processing of their precursor proteins by the serine proprotein convertases (PCs) in order to mediate their biological functions. These include adhesion molecules, proteases, growth factors, cytokines and their receptors. Since their discovery, the identification of new PCs substrates and specific PCs inhibitors became an attractive strategy in cancer therapy. In this review, we will report the implication of these enzymes and the processing of their substrates in tumor progression and metastasis. Newly reported studies on the potential use of the PCs as new therapeutic targets will be also discussed.
Keywords: Proprotein Convertases, furin, PACE4, PC5, PC7, cancer, metastasis, inhibitors, prosegments
Rights & PermissionsPrintExport